<DOC>
	<DOCNO>NCT00091975</DOCNO>
	<brief_summary>The objective study determine safety efficacy Zemplar® Capsule versus placebo , decrease elevate intact parathyroid hormone level chronic kidney disease stage 5 subject secondary hyperparathyroidism hemodialysis peritoneal dialysis , use revise dose titration scheme .</brief_summary>
	<brief_title>Zemplar® Capsule Reducing Serum Intact Parathyroid Hormone Levels Chronic Kidney Disease Stage 5 Subjects Hemodialysis Peritoneal Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Inclusion Criteria Subject least 18 year age , diagnose CKD Stage 5 undergo HD PD . If female , subject either childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) , childbearing potential practice 1 protocol specify method birth control , breastfeed negative serum pregnancy test prior Treatment Phase . For subject take phosphate binder prior study , subject stable ( type dose ) phosphate binder least 4 week prior Pretreatment Phase . For entry Pretreatment Phase , subject must calcium level &lt; = 10.5 mg/dL CaxP level &lt; = 65 mg2/dL2 . For entry Treatment Phase , subject must iPTH &gt; = 300 pg/mL ( determined Nichols iPTH assay ) , calcium level 8.0 10.5 mg/dL , inclusive , CaxP &lt; = 65 mg2/dL2 . Subject voluntarily sign date informed consent , approve Institutional Review Board ( IRB ) , nature study explain subject opportunity ask question . The informed consent sign studyspecific procedure perform medication withhold . Additional criterion HD subject include follow : subject diagnose CKD Stage 5 must maintenance HD 3 time week ( TIW ) least 2 month prior Screening Phase expect remain HD duration study . Additional criterion PD subject , include following : subject diagnose CKD Stage 5 must continuous PD ( either continuous cycle peritoneal dialysis [ CCPD ] , continuous ambulatory peritoneal dialysis [ CAPD ] , combination 2 ) 7 day per week least 2 month prior Screening Phase expect remain PD regimen duration study . Exclusion Criteria Subject history allergic reaction significant sensitivity drug similar study drug . Subject receive partial parathyroidectomy within 1 year prior Screening Phase . Subject acute renal failure within 3 month Screening Phase . Subject chronic gastrointestinal disease , investigator 's opinion , may result clinically significant gastrointestinal malabsorption . Subject take aluminumcontaining phosphate binder &gt; 3 week last 3 month prior Screening Phase , require medication &gt; 3 week study . Subject current malignancy ( exception basal squamous cell carcinoma skin ) , clinically significant liver disease , opinion investigator . Subject history drug alcohol abuse within 6 month prior Screening Phase . Subject evidence poor compliance diet , medication HD/PD may interfere , investigator 's opinion , adherence protocol . Subject participate investigational drug device study within 4 week prior Treatment Phase . Subject take calcitonin , maintenance IV oral glucocorticoid , cinacalcet , bisphosphonates , vitamin D compound ( study drug ) , drug may affect calcium bone metabolism , females stable estrogen and/or progestin therapy . Subject know human immunodeficiency virus ( HIV ) positive . For reason , subject consider investigator unsuitable candidate receive Zemplar . Additional exclusion criterion PD subject , : Subject active peritonitis within 1 month prior Screening Phase ; Subject 1 episode peritonitis within 4 month prior Screening Phase .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
</DOC>